|Systematic (IUPAC) name|
Meclonazepam ((S)-3-methylclonazepam) was discovered by a team at Hoffmann-La Roche in the 1970s and is a drug which is a benzodiazepine derivative similar in structure to clonazepam. It has sedative and anxiolytic actions like those of other benzodiazepines, and also has anti-parasitic effects against the parasitic worm Schistosoma mansoni.
- U.S. Patent 4,031,078
- The Lundbeck Institute. "Meclonazepam". Psychotropics. Lundbeck.
- Ansseau, M.; Doumont, A.; Thiry, D.; Von Frenckell, R.; Collard, J. (1985). "Initial study of methylclonazepam in generalized anxiety disorder. Evidence for greater power in the cross-over design". Psychopharmacology 87 (2): 130–135.
- O'Boyle, C.; Lambe, R.; Darragh, A. (1985). "Central Effects in Man of the Novel Schistosomicidal Benzodiazepine Meclonazepam". European Journal of Clinical Pharmacology 29 (1): 105–108.
- Abdul-Ghani, R. A.; Loutfy, N.; Hassan, A. (2009). "Experimentally promising antischistosomal drugs: A review of some drug candidates not reaching the clinical use". Parasitology Research 105 (4): 899–906.